Application of metabolic PET imaging in radiation oncology

Radiation Research

Volumn 177, Issue 4, 2012, Pages 436-448

  Zhu, Aizhi ^a   Marcus, David M ^a   Shu, Hui Kuo G ^a   Shim, Hyunsuk ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CHOLINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHIONINE; PACLITAXEL; VINBLASTINE;

BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGUS CANCER; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LUNG CANCER; LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; REVIEW; TISSUE METABOLISM; TREATMENT PLANNING;

ACETATES; CARBON RADIOISOTOPES; CARCINOMA; CHOLINE; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; INFLAMMATION; LYMPHOMA; MALE; METHIONINE; MOLECULAR IMAGING; NEOPLASMS; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84859775475     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2702.1     Document Type: Review

References (79)

1. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M. PETbased treatment planning in radiotherapy: a new standard? J Nucl Med 2007; 48 Suppl 1:68S-77S. (Pubitemid 47604944)
2. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 2011; 38:55-69.
3. Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 2009; 50:1655-65.
4. Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, et al. The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 2010; 186:471-81.
5. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233:93-100. (Pubitemid 39280962)
6. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-15. (Pubitemid 26340597)
7. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, et al. PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging 2006; 33:420-7.
8. Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, et al. 11C-acetate PET imaging of lung cancer: comparison with 18FFDG PET and 99mTc-MIBI SPET. Eur J Nucl Med Mol Imaging 2004; 31:13-21. (Pubitemid 38133536)
9. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003; 44:556-8. (Pubitemid 39663422)
10. Sun A, Sorensen J, Karlsson M, Turesson I, Langstrom B, Nilsson P, et al. 1-[11C]-acetate PET imaging in head and neck cancer-a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 2007; 34:651-7. (Pubitemid 46669365)
11. Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol 2010; 96:347-50.
12. Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011; 30:546-55.
13. Haubner R. PET radiopharmaceuticals in radiation treatment planning-synthesis and biological characteristics. Radiother Oncol 2010; 96:280-7.
14. Oyen WJ, Bussink J, Verhagen AF, Corstens FH, Bootsma GP. Role of FDG-PET in the diagnosis and management of lung cancer. Expert Rev Anticancer Ther 2004; 4:561-7. (Pubitemid 39161989)
15. Pommier P, Touboul E, Chabaud S, Dussart S, Le Pechoux C, Giammarile F, et al. Impact of 18F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study. AJR Am J Roentgenol 2010; 195:350-5.
16. Greco C, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007; 57:125-34. (Pubitemid 47043188)
17. Faria SL, Menard S, Devic S, Sirois C, Souhami L, Lisbona R, et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys 2008; 70:1035-8. (Pubitemid 351296113)
18. Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, et al. The impact of 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined nonsmall-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52:339-50. (Pubitemid 34172999)
19. Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp LJ, Comans EF, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006; 64:435-48. (Pubitemid 43083430)
20. Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004; 18:669-74. (Pubitemid 40215915)
21. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, ET AL. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004; 60:412-8. (Pubitemid 39233459)
22. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49:95-108. (Pubitemid 40798098)
23. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol 2008; 97:649-52. (Pubitemid 351812964)
24. Dandekar P, Partridge M, Kazi R, Nutting C, Harrington K, Newbold K. Challenges in integrating 18FDG PET-CT into radiotherapy planning of head and neck cancer. Indian J Cancer 2010; 47:260-6.
25. Gregoire V, Bol A, Geets X, Lee J. Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. Semin Radiat Oncol 2006; 16:232-8. (Pubitemid 44436964)
26. Troost EG, Schinagl DA, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJ, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010; 51:66-76.
27. Guido A, Fuccio L, Rombi B, Castellucci P, Cecconi A, Bunkheila F, et al. Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73:759-63.
28. Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, et al. Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol 2008; 47:1229-36.
29. Deantonio L, Beldi D, Gambaro G, Loi G, Brambilla M, Inglese E, et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008; 3:29.
30. Moule RN, Kayani I, Moinuddin SA, Meer K, Lemon C, Goodchild K, et al. The potential advantages of 18FDG PET/CTbased target volume delineation in radiotherapy planning of head and neck cancer. Radiother Oncol 2010; 97:189-93.
31. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57:853-63. (Pubitemid 37194314)
32. Sun A, Johansson S, Turesson I, Dasu A, Sorensen J. Imaging tumor perfusion and oxidative metabolism in patients with headand-neck cancer using 1-[11C]-acetate PET during radiotherapy: Preliminary results. Int J Radiat Oncol Biol Phys 2011 Jan 13. [Epub ahead of print]
33. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003; 30:63-71. (Pubitemid 36692894)
34. Farrag A, Ceulemans G, Voordeckers M, Everaert H, Storme G. Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 2010; 31:495-501.
35. Ford EC, Lavely WC, Frassica DA, Myers LT, Asrari F, Wahl RL, et al. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys 2008; 71:595-602.
36. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999; 210:807-14. (Pubitemid 29124045)
37. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-32. (Pubitemid 38552885)
38. Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, et al. [Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDGPET) image fusion for conformal radiotherapy in esophageal carcinoma]. Cancer Radiother 2005; 9:152-60. (Pubitemid 40979666)
39. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004; 73:269-75. (Pubitemid 39601073)
40. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18Ffluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009; 73:136-41.
41. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, et al. Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2010; 76:1235-41.
42. Schreurs LM, Busz DM, Paardekooper GM, Beukema JC, Jager PL, Van der Jagt EJ, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition. Dis Esophagus 2010; 23:493-501.
43. Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT, et al. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol 2010; 97:165-71.
44. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002; 4:301-10. (Pubitemid 35214593)
45. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 254:707-17.
46. Ngamruengphong S, Sharma VK, Nguyen B, Das A. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography. Dis Esophagus 2010; 23:216-31.
47. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916-27. (Pubitemid 350074687)
48. Divgi C. Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol 2005; 32 Suppl 1:S11-8. (Pubitemid 40409899)
49. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005; 25:191-207. (Pubitemid 40186951)
50. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 2007; 78:206-12.
51. Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 2007; 85:178-86. (Pubitemid 350160993)
52. Asakura H, Togami T, Mitani M, Takashima H, Yokoe K, Yamamoto Y, et al. Usefulness of FDG-PET imaging for the radiotherapy treatment planning of pyothorax-associated lymphoma. Ann Nucl Med 2005; 19:725-8. (Pubitemid 43175535)
53. Yao H, Cen XN, Liang ZY, Ou JP, Qiu ZX, Wang WS, et al. Application of SPECT/PET to 70 patients with lymphoma: monitoring response to therapy. Zhonghua Xue Ye Xue Za Zhi 2010, 31:667-70.
54. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50 Suppl 1:21S-30S.
55. Keller H, Goda JS, Vines DC, Lockwood G, Tsang R. Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging. Int J Radiat Oncol Biol Phys 2010; 76:850-8.
56. Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J. 11C-Lmethionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008; 10:1-18.
57. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46:1948-58. (Pubitemid 46657440)
58. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, etal. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39:778-85. (Pubitemid 28216722)
59. Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, etal. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004; 75:1457-62. (Pubitemid 39279817)
60. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, etal. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63:511-9. (Pubitemid 41317169)
61. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, etal. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63:64-74. (Pubitemid 41583543)
62. Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:339-44. (Pubitemid 44332720)
63. van den Bergh AC, Pruim J, Links TP, van der Vliet AM, Sluiter W, Wolffenbuttel BH, et al. Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy. Radiother Oncol 2011; 98:213-6.
64. Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999; 40:331-8. (Pubitemid 29077098)
65. Chiti A, Picchio M. The rising PET: the increasing use of choline PET/CT in prostate cancer. Eur J Nucl Med Mol Imaging 2011;38:53-4.
66. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54:392-401.
67. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, et al. [11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009; 27:619-25.
68. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010; 24:485-92.
69. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, et al. [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008; 35:689-95.
70. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:549-55. (Pubitemid 39663421)
71. Soloviev D, Fini A, Chierichetti F, Al-Nahhas A, Rubello D. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 2008; 35:942-9.
72. Morris MJ, Scher HI. 11C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:181-4. (Pubitemid 46147500)
73. Seppala J, Seppanen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009; 93:234-40.
74. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:253-63.
75. Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol 2009; 4:34.
76. Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 2011; 259:852-61.
77. Savir-Baruch B, Schuster DM, Jarkas N, Master VA, Nieh PT, Halkar RK, et al. Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PETCT in recurrent prostate carcinoma. Mol Imaging Biol 2010 Oct 26. DOI: 10.1007/s11307-010-0445-3.
78. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1- carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48:56-63. (Pubitemid 47555376)
79. Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007; 48:46-55. (Pubitemid 47555375)